In Shanghai, China on December 12, 2018, the self-developed VitaFlow^® II Transcatheter Aortic Valve and Recyclable Delivery System of MicroPort^® Cardioflow has been admitted into the “Green Path”from National Medical Products Administration (NMPA) for the special approval procedure for innovative medical devices. 

In Galway, Ireland on December 11, 2018, Shanghai MicroPort^® CardioFlow Medtech Co., Ltd. (hereinafter referred to as “MicroPort^® CardioFlow”) announced that the first patient enrollment was completed in Europe for the project of pre-market clinical research on its self-developed VitaFlow^® II Transcatheter Aortic Valve and Recyclable Delivery System (hereinafter referred to as “VitaFlow™ II System”) (“VITALE” project for short).

Shanghai, China - VitaFlow^® Transcatheter Aortic Valve and Delivery System ("VitaFlow^®"), in-house developed by MicroPort CardioFlow has been admitted into the "Green Path" by the China Food and Drug Administration ("CFDA"), a special fast-track procedure for innovative medical devices to gain CFDA approval.